TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants
Citation:
Higgins, S.C., Mills, K.H.G, TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants, Current Infectious Disease Reports, 12, 1, 2010, 4-12Download Item:
Abstract:
Vaccines based on attenuated or killed viruses and bacteria are highly effective in preventing
infection with a range of pathogens, but can have safety issues. Therefore, there is a move
towards subunit vaccines based on recombinant proteins or naked DNA. However, protein
subunit vaccines are typically poorly immunogenic when administered alone and therefore
require co-administration with adjuvants to boost the immune response. For many decades
there was very little progress in understanding the mechanism of action of adjuvants, but
recently there have been a number of significant breakthroughs in this area. The binding of
pathogen-derived molecules to different immune sensors, including Toll-like receptors (TLR)
and nucleotide-binding oligomerization domain-like receptors (NLR) and retinoic acidinducible
protein-1-like receptors (RLR), activate important innate immune pathways and
provide us with not only an understanding of how current vaccines and adjuvants work, but
also provide potential targets for novel adjuvant development.
Sponsor
Grant Number
European Commission
NASPANVAC
Science Foundation Ireland (SFI)
Author's Homepage:
http://people.tcd.ie/millskDescription:
PUBLISHED
Author: MILLS, KINGSTON; HIGGINS, SARAH
Type of material:
Journal ArticleCollections
Series/Report no:
Current Infectious Disease Reports12
1
Availability:
Full text availableKeywords:
Immunology, Vaccine, Adjuvant, TLR, NLRSubject (TCD):
Immunology, Inflammation & InfectionMetadata
Show full item recordLicences: